Dexcom

DexCom, Inc. (Nasdaq: DXCM) is a leading medical device company that develops, manufactures, and sells continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1999 and headquartered in San Diego, California, Dexcom has emerged as a pioneer in diabetes care technology.

Dexcom's primary products are its CGM systems, which include the G6 and G7 models. These devices use a small sensor inserted under the skin to continuously monitor glucose levels and transmit real-time data to a smartphone app or receiver. The G6 sensor can be worn for up to 10 days, while the G7 offers a 30-minute warmup time - the fastest of any CGM on the market. Dexcom's CGMs do not require fingerstick calibrations and can be used to make treatment decisions. Other key features include customizable alerts, remote monitoring capabilities, and integration with insulin pumps.

In 2023, Dexcom reported preliminary unaudited revenue of approximately USD 3.62 billion, representing 24% growth over the previous year. The company has expanded coverage for its devices, with its CGMs now reimbursed by over 97% of private insurance as well as Medicare nationwide. Looking ahead to 2024, Dexcom anticipates revenue between USD 4.15 billion and USD 4.35 billion as it aims to launch Stelo, its first CGM product designed for people with type two diabetes who do not use insulin. Dexcom continues to focus on expanding CGM access and awareness while developing new products to serve a broader range of patients managing diabetes.